| Patient | Higuchi Ichiyō |
|---|---|
| Date of birth | 1872-05-02 |
| Identifiers | MRN HR-NI029-SYN-TD; SSN (made up) 000-29-5108 |
| Document date | 1896-05-01 |
| Author | Aiko Lindgren-Tanaka, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-week review on tuberculosis treatment. [S]
Ms. Higuchi returns two weeks into treatment. She has taken all fourteen doses on daily video calls with the public health center nurse. The evening fevers stopped about ten days in, the night sweats are lighter, and the cough is less frequent and dry. She had mild nausea after the morning doses in the first week, which went once she moved them to bedtime with a small snack. Her urine and tears are orange, as expected. She has no yellowing, dark urine, abdominal pain, rash, numbness, or change in vision or colors. The liquid culture from her first sputum specimen grew Mycobacterium tuberculosis complex after twelve days. She is eating three meals and two snacks a day with the supplement drinks. The public funding was approved. She has begun to write again for about an hour each morning. [S]
| Element | Detail |
|---|---|
| Treatment | Fourteen of fourteen doses observed by video |
| Symptoms | No fever for four days; lighter night sweats; less cough |
| Side effects | Mild nausea in the first week, gone with bedtime dosing; orange urine and tears |
| Culture | Mycobacterium tuberculosis complex grown from the first specimen |
| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Occasional dry cough; no blood; less breathless |
| Constitutional | Positive | Lighter night sweats; no fever for four days; appetite better |
| Gastrointestinal | Negative | No nausea now; no vomiting, abdominal pain or jaundice |
| Eyes | Negative | No blurred vision or change in colors |
| Neurological | Negative | No numbness or tingling |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Isoniazid 100 mg tablets, two tablets (200 mg) daily | 200 mg once daily, observed by video each day through the public health center's directly observed treatment program, for 26 weeks | Oral route | 1896-04-17 to 1896-10-15 | completed | S |
| Rifampin (rifampicin) 150 mg capsules, three capsules (450 mg) daily | 450 mg once daily on an empty stomach, observed by video each day through the public health center's directly observed treatment program, for 26 weeks | Oral route | 1896-04-17 to 1896-10-15 | completed | S |
| Pyrazinamide 500 mg tablets, two tablets (1000 mg) daily | 1000 mg once daily, observed by video each day through the public health center's directly observed treatment program, for the eight-week intensive phase | Oral route | 1896-04-17 to 1896-06-11 | completed | S |
| Ethambutol 100 mg tablets, six tablets (600 mg) daily | 600 mg once daily, observed by video each day through the public health center's directly observed treatment program, until susceptibility results return | Oral route | 1896-04-17 to 1896-05-22 | stopped | S |
| Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily | 50 mg once daily with isoniazid | Oral route | 1896-04-17 to 1896-10-15 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1896-05-01 | Body height | 148 | cm | S |
| 1896-05-01 | Body weight | 39.2 | kg | S |
| 1896-05-01 | Body mass index (BMI) [Ratio] | 17.9 | kg/m2 | S |
| 1896-05-01 | Systolic blood pressure | 100 | mm[Hg] | S |
| 1896-05-01 | Diastolic blood pressure | 62 | mm[Hg] | S |
| 1896-05-01 | Heart rate | 90 | /min | S |
| 1896-05-01 | Respiratory rate | 18 | /min | S |
| 1896-05-01 | Body temperature | 37.1 | Cel | S |
| 1896-05-01 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1896-05-01 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 7-35 U/L | Normal | S |
| 1896-05-01 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 10-35 U/L | Normal | S |
| 1896-05-01 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 1896-05-01 | Visual acuity uncorrected Right eye by ETDRS eye chart | 85 | {letters} | >=80 | Normal | S |
| 1896-05-01 | Visual acuity uncorrected Left eye by ETDRS eye chart | 84 | {letters} | >=80 | Normal | S |
Vital signs recorded on 1896-05-01; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Less tired; weight 39.2 kg, up 0.7 kg; temperature 37.1 °C, pulse 90 |
| Eyes | No icterus. Visual acuity 85 letters on the right and 84 on the left; Ishihara plates read correctly with each eye |
| Respiratory | A few fine crackles over the right upper zone, fewer than at diagnosis |
| Abdomen | Soft and non-tender; liver not enlarged |
| Neurological | Normal sensation and reflexes in the feet |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Cough for about seven weeks with evening fevers, night sweats, poor appetite and weight loss of about 4 kg (about 10 percent) in a woman of 23; chest X-ray with patchy right upper lobe opacities and no cavity; suspected pulmonary tuberculosis; airborne precautions and three sputum specimens for acid-fast smear, nucleic acid amplification and culture | resolved | confirmed | R05.3 | S — Synthetic presenting problem at intake, superseded by the diagnosis at the second visit; its timing echoes her documented decline from early 1896 (D). |
| Pulmonary tuberculosis of the right upper lobe, sputum smear-negative, confirmed by Xpert MTB/RIF Ultra (Mycobacterium tuberculosis detected, low; rifampin resistance not detected) | active | confirmed | A15.0 | S — Synthetic modern coding of her documented tuberculosis; all bacteriology and imaging are synthetic. |
| Moderate protein-calorie malnutrition: BMI 17.6, about 10 percent weight loss in two months, and albumin 3.3 g/dL | active | confirmed | E44.0 | S — Synthetic nutrition diagnosis at intake, anchored to her documented poverty. |
| Low and irregular income from writing, with a household to support; costs of care are a barrier | active | confirmed | Z59.6 | S — Synthetic social need anchored to her documented poverty and household responsibilities. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Symptom review: cough, sputum, fever, night sweats | At least monthly during treatment | Completed today | No fever for four days; lighter night sweats; occasional dry cough |
| Self-management | Weight and nutrition | Every visit; dose review if weight changes by more than about 5 kg | Completed today | 39.2 kg, up 0.7 kg; doses unchanged |
| Medication safety | Hepatitis symptom review (nausea, vomiting, abdominal pain, jaundice, dark urine) | Every visit and every observed dose | Completed today | Mild nausea in the first week only; no jaundice, dark urine or pain |
| Laboratory | Liver tests (ALT, AST, bilirubin) | Baseline; at two weeks and monthly in the intensive phase because of low weight and albumin; then for symptoms | Completed today | ALT 22, AST 24 U/L, bilirubin 0.6 mg/dL, all normal |
| Imaging | Visual acuity and color vision | Baseline and monthly while on ethambutol | Completed today | 85 letters on the right and 84 on the left; color vision normal |
| Laboratory | Sputum smear and culture | At diagnosis, at two weeks, and at the end of the intensive phase (two months) | Completed today | Liquid culture of the first specimen grew Mycobacterium tuberculosis complex at twelve days; two-week specimen sent today |
| Laboratory | Drug susceptibility testing of the first isolate | Once, on the first positive culture | Ordered | Set up on the isolate; result expected in about three weeks |
| Medication safety | Doses observed and missed (video-observed therapy) | Every visit | Completed today | Fourteen of fourteen doses observed |
| Medication safety | Peripheral neuropathy check, with pyridoxine | Every visit | Completed today | No neuropathy; pyridoxine 50 mg daily |
| Medication safety | Rifampin drug-interaction review, including hormonal contraception | With every new medicine | Completed today | No new medicines |
| Self-management | Home precautions and the criteria for release | Until two weeks of treatment with clinical improvement, for smear-negative disease | Completed today | Released from home precautions today with the public health center's agreement |
| Referral | Contact investigation (household and close contacts) | Led by the public health center, from diagnosis | Referred | Under way with the public health center; results not part of her record |
| Referral | Public funding and other help with costs | At diagnosis and as needed | Completed today | Public funding approved |
| Survey | Depression screen (PHQ-9) | At diagnosis, at two months, and at the end of treatment | Up to date | PHQ-9 8 at intake; next at two months |
Goal progress:
Guideline basis: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment (2022); Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children (2017); An official ATS statement: hepatotoxicity of antituberculosis therapy (2006); Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005); 結核 (Tuberculosis): notification criteria under Article 12 of the Infectious Diseases Control Law (current); 結核医療費の公費負担 (Public funding of tuberculosis medical costs under Articles 37 and 37-2 of the Infectious Diseases Control Law) (current); Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition) (2012)
Follow-up: Ethambutol stopped by phone when susceptibility results return. Monthly liver tests. End-of-intensive-phase review at eight weeks with the two-month sputum. Call the same day for hepatitis symptoms or any change in vision. Next scheduled visit 1896-06-12: end of the eight-week intensive phase: susceptibility results, the two-month sputum culture, and the start of the continuation phase. [S]